Q4 2025 · 13F-HR
STEMPOINT CAPITAL LPholdings as filed
Filed 2026-02-17 · accession 0001420506-26-000490
$583.2M
Reported value
77
Positions
2025-12-31
Period end
The Brief · STEMPOINT CAPITAL LP · Q4 2025
AI · grounded in 13F
STEMPOINT CAPITAL LP closed its position in BIOHAVEN LTD, reducing its exposure by $16.46M. The fund established a new position in Twist Bioscience Corp TWST valued at $16.44M. Other significant moves include increasing its stake in Arcellx Inc ACLXGBX by 2,825.98% and exiting positions in Wave Life Sciences Ltd and Cidara Therapeutics Inc.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 00370M103 | ABVX | ABIVAX SA | $52.8M | 9.06% | 391,783 | Common | SOLE |
| 80706P103 | SRRK | SCHOLAR ROCK HLDG CORP | $39.1M | 6.70% | 886,893 | Common | SOLE |
| 152309100 | CNTA | CENTESSA PHARMACEUTICALS PLC | $28.9M | 4.95% | 1,154,114 | Common | SOLE |
| 87164F105 | SNDX | SYNDAX PHARMACEUTICALS INC | $28.1M | 4.83% | 1,339,379 | Common | SOLE |
| 86366E106 | GPCR | STRUCTURE THERAPEUTICS INC | $24.4M | 4.19% | 351,073 | Common | SOLE |
| 03940C100 | ACLXGBX | ARCELLX INC | $21.7M | 3.72% | 332,860 | Common | SOLE |
| G76279101 | ROIV | ROIVANT SCIENCES LTD | $21.0M | 3.60% | 966,698 | Common | SOLE |
| 880881107 | 430 | TERNS PHARMACEUTICALS INC | $17.3M | 2.97% | 429,198 | Common | SOLE |
| 90184D100 | TWST | TWIST BIOSCIENCE CORP | $16.4M | 2.82% | 518,355 | Common | SOLE |
| 45258J102 | IMVT | IMMUNOVANT INC | $16.4M | 2.81% | 644,959 | Common | SOLE |
| 26818M108 | DYN | DYNE THERAPEUTICS INC | $16.3M | 2.80% | 835,200 | Common | SOLE |
| 98420N105 | XENE | XENON PHARMACEUTICALS INC | $15.6M | 2.68% | 348,605 | Common | SOLE |
| 86889P208 | SRZN | SURROZEN INC | $12.7M | 2.17% | 619,766 | Common | SOLE |
| 15102K100 | CELC | CELCUITY INC | $11.8M | 2.02% | 118,333 | Common | SOLE |
| 603170101 | MLYS | MINERALYS THERAPEUTICS INC | $10.5M | 1.80% | 290,049 | Common | SOLE |
| 558868105 | MDGL | MADRIGAL PHARMACEUTICALS INC | $10.3M | 1.77% | 17,736 | Common | SOLE |
| 00650F109 | ADPT | ADAPTIVE BIOTECHNOLOGIES COR | $9.9M | 1.69% | 606,825 | Common | SOLE |
| 696389402 | PALI | PALISADE BIO INC | $9.9M | 1.69% | 4,192,375 | Common | SOLE |
| 23282W605 | CYTK | CYTOKINETICS INC | $9.3M | 1.60% | 146,978 | Common | SOLE |
| 28036F105 | EWTX | EDGEWISE THERAPEUTICS INC | $9.0M | 1.54% | 360,876 | Common | SOLE |
| 10919W405 | DRUG | BRIGHT MINDS BIOSCIENCES INC | $7.6M | 1.30% | 97,340 | Common | SOLE |
| 640268306 | NKTR | NEKTAR THERAPEUTICS | $7.5M | 1.29% | 178,274 | Common | SOLE |
| 478160104 | JNJ | JOHNSON & JOHNSON | $7.2M | 1.24% | 35,000 | Common | SOLE |
| 24823R105 | DNLI | DENALI THERAPEUTICS INC | $6.9M | 1.19% | 419,058 | Common | SOLE |
| 03237H101 | AMLX | AMYLYX PHARMACEUTICALS INC | $6.8M | 1.17% | 565,140 | Common | SOLE |
| 18507C103 | CLPT | CLEARPOINT NEURO INC | $6.6M | 1.13% | 481,858 | Common | SOLE |
| 03969K108 | ARQT | ARCUTIS BIOTHERAPEUTICS INC | $6.5M | 1.12% | 224,740 | Common | SOLE |
| 30233G209 | EYPT | EYEPOINT INC | $6.5M | 1.11% | 353,849 | Common | SOLE |
| N44445109 | IMTX | IMMATICS N.V | $6.4M | 1.10% | 610,308 | Common | SOLE |
| 67576A100 | OCUL | OCULAR THERAPEUTIX INC | $6.3M | 1.09% | 522,693 | Common | SOLE |
| 76243J105 | RYTM | RHYTHM PHARMACEUTICALS INC | $6.3M | 1.08% | 58,915 | Common | SOLE |
| 74006W207 | PRAX | PRAXIS PRECISION MEDICINES I | $6.2M | 1.06% | 21,067 | Common | SOLE |
| 03770N101 | APGE | APOGEE THERAPEUTICS INC | $6.1M | 1.04% | 80,574 | Common | SOLE |
| 45337C102 | INCY | INCYTE CORP | $6.1M | 1.04% | 61,435 | Common | SOLE |
| 45166A102 | IDYA | IDEAYA BIOSCIENCES INC | $5.6M | 0.96% | 161,659 | Common | SOLE |
| 045396207 | ASMB | ASSEMBLY BIOSCIENCES INC | $5.3M | 0.91% | 156,728 | Common | SOLE |
| 578784100 | MAZE | MAZE THERAPEUTICS INC | $5.2M | 0.89% | 125,877 | Common | SOLE |
| 74366E102 | PTGX | PROTAGONIST THERAPEUTICS INC | $5.2M | 0.89% | 59,430 | Common | SOLE |
| 532457108 | LLY | ELI LILLY & CO | $5.1M | 0.88% | 4,759 | Common | SOLE |
| 89532M101 | TRVI | TREVI THERAPEUTICS INC | $5.0M | 0.86% | 399,557 | Common | SOLE |
| 76155X100 | RVMD | REVOLUTION MEDICINES INC | $4.9M | 0.85% | 62,032 | Common | SOLE |
| 92790C104 | VRDN | VIRIDIAN THERAPEUTICS INC | $4.8M | 0.82% | 154,320 | Common | SOLE |
| 03879J100 | ABUS | ARBUTUS BIOPHARMA CORP | $4.7M | 0.81% | 986,751 | Common | SOLE |
| 61559X104 | MLTX | MOONLAKE IMMUNOTHERAPEUTICS | $4.6M | 0.79% | 348,401 | Common | SOLE |
| 23284F105 | CTMX | CYTOMX THERAPEUTICS INC | $4.4M | 0.76% | 1,036,311 | Common | SOLE |
| 98420X202 | XFOR | X4 PHARMACEUTICALS INC | $3.6M | 0.62% | 898,465 | Common | SOLE |
| 00032Q104 | WHWK | WHITEHAWK THERAPEUTICS INC | $3.5M | 0.61% | 1,458,807 | Common | SOLE |
| 252828108 | DNTH | DIANTHUS THERAPEUTICS INC | $3.3M | 0.56% | 79,284 | Common | SOLE |
| 04351P101 | ASNDUSD | ASCENDIS PHARMA A/S | $3.2M | 0.54% | 14,842 | Common | SOLE |
| 759916109 | RGEN | REPLIGEN CORP | $2.6M | 0.44% | 15,707 | Common | SOLE |
| N62509109 | NAMS | NEWAMSTERDAM PHARMA COMPANY | $2.6M | 0.44% | 73,106 | Common | SOLE |
| 55287L101 | MBX | MBX BIOSCIENCES INC | $2.5M | 0.42% | 78,553 | Common | SOLE |
| 22053A107 | — | QUINCE THERAPEUTICS INC | $2.5M | 0.42% | 739,264 | Common | SOLE |
| 05338F306 | AVTX | AVALO THERAPEUTICS INC | $2.5M | 0.42% | 135,552 | Common | SOLE |
| 00534A102 | IVVD | INVIVYD INC | $2.4M | 0.42% | 989,822 | Common | SOLE |
| G59665102 | MGTX | MEIRAGTX HLDGS PLC | $2.3M | 0.39% | 287,689 | Common | SOLE |
| 46124U107 | IVA | INVENTIVA SA | $2.2M | 0.37% | 467,242 | Common | SOLE |
| 00287Y109 | ABBV | ABBVIE INC | $2.1M | 0.37% | 9,325 | Common | SOLE |
| H0036K147 | ADCT | ADC THERAPEUTICS SA | $1.8M | 0.30% | 502,570 | Common | SOLE |
| 56565P103 | MPLT | MAPLIGHT THERAPEUTICS INC | $1.8M | 0.30% | 100,000 | Common | SOLE |
| N69605108 | PHVS | PHARVARIS N V | $1.6M | 0.28% | 58,389 | Common | SOLE |
| 52490G102 | LEGN | LEGEND BIOTECH CORP | $1.6M | 0.27% | 73,328 | Common | SOLE |
| 07782B104 | BLTE | BELITE BIO INC | $1.5M | 0.25% | 9,163 | Common | SOLE |
| 98422T100 | — | XILIO THERAPEUTICS INC | $1.3M | 0.22% | 2,030,028 | Common | SOLE |
| 30054Y107 | EVMN | EVOMMUNE INC | $1.2M | 0.20% | 68,196 | Common | SOLE |
| 107924102 | BBOT | BRIDGEBIO ONCOLOGY THERAPEUT | $1.1M | 0.19% | 86,517 | Common | SOLE |
| 00773J202 | SYRE | SPYRE THERAPEUTICS INC | $1.1M | 0.18% | 32,377 | Common | SOLE |
| N90064101 | QURE | UNIQURE NV | $1.0M | 0.18% | 43,485 | Common | SOLE |
| 877619106 | TSHA | TAYSHA GENE THERAPIES INC | $1.0M | 0.17% | 182,130 | Common | SOLE |
| 61225M102 | GLUE | MONTE ROSA THERAPEUTICS INC | $965,527 | 0.17% | 61,577 | Common | SOLE |
| 78397T202 | SABS | SAB BIOTHERAPEUTICS INC | $548,127 | 0.09% | 146,558 | Common | SOLE |
| 921659108 | VNDA | VANDA PHARMACEUTICALS INC | $520,283 | 0.09% | 58,989 | Common | SOLE |
| 14070B309 | CAPR | CAPRICOR THERAPEUTICS INC | $515,238 | 0.09% | 17,853 | Common | SOLE |
| 80706P103 | SRRK | SCHOLAR ROCK HLDG CORP | $484,750 | 0.08% | 277,000 | CALL | SOLE |
| 70261F202 | KTTA | PASITHEA THERAPEUTICS CORP | $458,056 | 0.08% | 355,082 | Common | SOLE |
| 92840H400 | VTGN | VISTAGEN THERAPEUTICS INC | $142,086 | 0.02% | 616,749 | Common | SOLE |
| 152309100 | CNTA | CENTESSA PHARMACEUTICALS PLC | $26,250 | 0.00% | 75,000 | CALL | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.